Aliases & Classifications for Plague

MalaCards integrated aliases for Plague:

Name: Plague 12 72 55 40 3 14 69
Yersiniosis 55 3
Yersinia Infections 69

Characteristics:

Orphanet epidemiological data:

55
plague
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:3482
ICD10 32 A20 A20.9
ICD9CM 34 020 020.9
MeSH 41 D010930
NCIt 46 C85015
Orphanet 55 ORPHA707
MESH via Orphanet 42 D010930 D015009
UMLS via Orphanet 70 C0032064 C0043407
ICD10 via Orphanet 33 A20.0 A20.1 A20.2 more

Summaries for Plague

MedlinePlus : 40 Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague: Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent. Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine. NIH: National Institute of Allergy and Infectious Diseases

MalaCards based summary : Plague, also known as yersiniosis, is related to bubonic plague and septicemic plague, and has symptoms including pruritus and fever. An important gene associated with Plague is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Kaposi's sarcoma-associated herpesvirus infection and Cell adhesion molecules (CAMs). The drugs Anticholesteremic Agents and Antimetabolites have been mentioned in the context of this disorder. Affiliated tissues include lymph node, vasculature or and lung, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A primary bacterial infectious disease that results_in infection, located in lymph node, located in vasculature or located in lungs, has material basis in Yersinia pestis, which is transmitted_by oriental rat flea (Xenopsylla cheopis) infected by feeding on rodents and other mammals, transmitted_by air, transmitted_by direct contact or transmitted_by ingestion of contaminated undercooked food.

CDC : 3 Plague is a disease that affects humans and other mammals. It is caused by the bacterium, Yersinia pestis. Humans usually get plague after being bitten by a rodent flea that is carrying the plague bacterium or by handling an animal infected with plague. Plague is infamous for killing millions of people in Europe during the Middle Ages. Today, modern antibiotics are effective in treating plague. Without prompt treatment, the disease can cause serious illness or death. Presently, human plague infections continue to occur in the western United States, but significantly more cases occur in parts of Africa and Asia.

Wikipedia : 72 Plague is an infectious disease caused by the bacterium Yersinia pestis. Symptoms include fever,... more...

Related Diseases for Plague

Diseases related to Plague via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Related Disease Score Top Affiliating Genes
1 bubonic plague 34.2 CCR5 PLG
2 septicemic plague 34.0 MYD88 PLG
3 pneumonic plague 33.6 PLG SULT1A2
4 tularemia 11.3
5 anthrax disease 10.9
6 myositis fibrosa 10.3 CD86 MYD88
7 blastic plasmacytoid dendritic cell 10.2 MYD88 PECAM1
8 pulmonary vein stenosis 10.2 PECAM1 TYMP
9 hemangioendothelioma 10.2 PECAM1 PLG
10 hydrocele 10.2 PECAM1 SELE
11 exanthema subitum 10.1 CD83 CD86
12 mycobacterium tuberculosis 1 10.1
13 endophthalmitis 10.0 PLG SELE
14 chronic myocardial ischemia 10.0 PLG TYMP
15 aging 10.0
16 cholera 10.0
17 episodic pain syndrome, familial, 1 9.9
18 ecthyma 9.9
19 typhoid fever 9.9
20 pneumonia 9.9
21 influenza 9.9
22 smallpox 9.9
23 polyarteritis nodosa 9.9 PECAM1 SELE
24 legionnaire disease 9.8
25 malaria 9.8
26 legionnaires' disease 9.8
27 relapsing fever 9.8
28 measles 9.8
29 keratitis, hereditary 9.7
30 migraine with or without aura 1 9.7
31 motion sickness 9.7
32 polykaryocytosis inducer 9.7
33 schistosoma mansoni infection, susceptibility/ 9.7
34 hemochromatosis, type 1 9.7
35 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.7
36 leprosy 3 9.7
37 macular degeneration, age-related, 1 9.7
38 kala-azar 1 9.7
39 multiple mitochondrial dysfunctions syndrome 5 9.7
40 crohn's disease 9.7
41 hepatitis 9.7
42 laryngotracheitis 9.7
43 swine influenza 9.7
44 endemic typhus 9.7
45 mucositis 9.7
46 thrombotic thrombocytopenic purpura 9.7
47 q fever 9.7
48 bartonellosis 9.7
49 dysentery 9.7
50 blastomycosis 9.7

Graphical network of the top 20 diseases related to Plague:



Diseases related to Plague

Symptoms & Phenotypes for Plague

UMLS symptoms related to Plague:


pruritus, fever

MGI Mouse Phenotypes related to Plague:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 CCR5 CD86 CDC25C DDX58 INVS MGAT1
2 cardiovascular system MP:0005385 10.09 CCR5 CD83 INVS MGAT1 MYD88 PECAM1
3 digestive/alimentary MP:0005381 9.97 CCR5 CDC25C DDX58 INVS MYD88 PECAM1
4 hematopoietic system MP:0005397 9.96 PLG SELE CCR5 CD83 CD86 DDX58
5 endocrine/exocrine gland MP:0005379 9.92 CD83 CD86 CDC25C INVS MGAT1 MYD88
6 homeostasis/metabolism MP:0005376 9.9 PTS SELE TYMP CCR5 CD86 DDX58
7 immune system MP:0005387 9.65 CCR5 CD83 CD86 DDX58 INVS MYD88
8 liver/biliary system MP:0005370 9.1 CCR5 DDX58 INVS PECAM1 PLG SELE

Drugs & Therapeutics for Plague

Drugs for Plague (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anticholesteremic Agents Phase 4
2 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
3 Calcium, Dietary Phase 4,Phase 3
4 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2
5 Hypolipidemic Agents Phase 4
6 Lipid Regulating Agents Phase 4
7 Rosuvastatin Calcium Phase 4 147098-20-2
8 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1
9 Aluminum phosphate Phase 4
10 Antacids Phase 4,Phase 1
11 Anti-Ulcer Agents Phase 4,Phase 1
12 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
13 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
14
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
15
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
16
Etanercept Approved, Investigational Phase 3 185243-69-0
17
Morphine Approved, Investigational Phase 3 57-27-2 5288826
18
Interferon beta-1a Approved, Investigational Phase 3 145258-61-3 6438354
19
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
20
Crizotinib Approved Phase 3,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
21
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
22
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
23 Racepinephrine Approved Phase 2, Phase 3 329-65-7
24
Oseltamivir Approved Phase 3,Phase 2 196618-13-0, 204255-11-8 65028
25
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
26
Etoposide Approved Phase 3,Phase 1,Phase 2,Early Phase 1 33419-42-0 36462
27
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
28
Methotrexate Approved Phase 3,Phase 2,Early Phase 1 1959-05-2, 59-05-2 126941
29
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
30
Cytarabine Approved, Investigational Phase 3,Early Phase 1 147-94-4 6253
31
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 657311 5754
32
Budesonide Approved Phase 3 51333-22-3 5281004 63006
33
Pimavanserin Approved, Investigational Phase 3,Phase 2 706779-91-1 16058810
34
Rivaroxaban Approved Phase 3 366789-02-8
35
Pembrolizumab Approved Phase 3 1374853-91-4
36
Sunitinib Approved, Investigational Phase 3 341031-54-7, 557795-19-4 5329102
37
Adalimumab Approved Phase 3 331731-18-1 16219006
38
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
39
Gemcitabine Approved Phase 3 95058-81-4 60750
40
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
41 Vedolizumab Approved Phase 3 943609-66-3
42
Pregabalin Approved, Illicit, Investigational Phase 3 148553-50-8 5486971
43
Dimethyl fumarate Approved, Investigational Phase 3 624-49-7 5271565 637568
44
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
45
Idarubicin Approved Phase 3 58957-92-9 42890
46
Lenograstim Approved, Investigational Phase 3 135968-09-1
47
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
48
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
49
Thrombin Approved, Investigational Phase 3
50
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096

Interventional clinical trials:

(show top 50) (show all 113)

# Name Status NCT ID Phase Drugs
1 Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging Unknown status NCT02041117 Phase 4 Rosuvastatin
2 Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons Completed NCT01404182 Phase 4
3 Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years Completed NCT01424228 Phase 4 placebo;prucalopride
4 School Inner-City Asthma Intervention Study (SICAS-2) Recruiting NCT02291302 Phase 4
5 EASY: Extended Access to Sollpura Over Years Recruiting NCT02823964 Phase 4 Liprotamase
6 Treatment and Diagnosis of Plague Completed NCT00128466 Phase 2, Phase 3 gentamicin;streptomycin
7 Mouse Allergen and Asthma Intervention Trial Completed NCT01251224 Phase 3
8 A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension Completed NCT00644605 Phase 3 sildenafil;sildenafil;placebo;sildenafil
9 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
10 Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy Completed NCT00676507 Phase 3
11 Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects Completed NCT02378506 Phase 3
12 Phase 3 Study of RPC1063 in Relapsing MS Completed NCT02294058 Phase 3 RPC1063;Beta interferon
13 Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study) Completed NCT02047734 Phase 3 RPC1063 0.5 mg;RPC1063 1 mg;RPC1063 placebo;Interferon β-1a;IFN β-1a placebo
14 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01212757 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
15 Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™ Completed NCT00445185 Phase 3
16 A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B. Completed NCT00291941 Phase 3
17 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed NCT01523587 Phase 3 afatinib;erlotinib
18 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed NCT00932893 Phase 3 PF-02341066;Pemetrexed;Docetaxel
19 Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns Recruiting NCT02700828 Phase 2, Phase 3 Hydrocortisone;Placebo
20 Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) Recruiting NCT02465567 Phase 3 BGF MDI 320/14.4/9.6 μg;GFF MDI 14.4/9.6 μg;BGF MDI 160/14.4/9.6 μg;BFF MDI 320/9.6 μg
21 Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications Recruiting NCT02949011 Phase 3 Baloxavir Marboxil;Placebo to Baloxavir Marboxil;Oseltamivir;Placebo to Oseltamivir
22 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) Recruiting NCT02970292 Phase 3 Pimavanserin;Placebo
23 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Recruiting NCT02111564 Phase 3 Rivaroxaban, 10 mg;Rivaroxaban, 7.5 mg;Placebo
24 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC Recruiting NCT03260894 Phase 3 Pembrolizumab;Epacadostat;Sunitinib;Pazopanib
25 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug Recruiting NCT03104400 Phase 3 Adalimumab;ABT-494;Placebo for ABT-494;Placebo for Adalimumab
26 A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Recruiting NCT03066778 Phase 3 Normal saline solution;Carboplatin;Cisplatin;Etoposide
27 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Recruiting NCT02819518 Phase 3 Nab-paclitaxel;Paclitaxel;Gemcitabine;Carboplatin;Normale Saline Solution
28 Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia Recruiting NCT03121586 Phase 3 Pimavanserin
29 RESULT: Reliable, Emergent Solution Using Liprotamase Treatment Recruiting NCT03051490 Phase 3 Liprotamase;porcine PERT
30 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) Recruiting NCT03162796 Phase 3 Guselkumab;Placebo
31 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT03114657 Phase 3 Crenezumab;Placebo
32 Vedolizumab Subcutaneous Long-Term Open-Label Extension Study Recruiting NCT02620046 Phase 3 Vedolizumab SC
33 Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease Recruiting NCT02611817 Phase 3 Vedolizumab SC 108 mg;Placebo;Vedolizumab IV 300 mg
34 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Recruiting NCT02413580 Phase 3
35 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3 etrolizumab
36 A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD) Recruiting NCT02394028 Phase 3 Etrolizumab;Placebo
37 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02165215 Phase 3 Etrolizumab;Placebo
38 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3 Etrolizumab
39 A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02100696 Phase 3 Etrozulimab;Placebo
40 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. Recruiting NCT01747915 Phase 3 Pregabalin Dose Level 1;Pregabalin Dose Level 2;Placebo
41 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) Recruiting NCT02907177 Phase 3 Ponesimod
42 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clon Recruiting NCT01463306 Phase 3 Pregabalin
43 A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Active, not recruiting NCT02706873 Phase 3 ABT-494 matching placebo;Methotrexate;Methotrexate matching placebo;ABT-494
44 A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Active, not recruiting NCT02629159 Phase 3 Placebo for Adalimumab;ABT-494;Adalimumab;Placebo for ABT-494
45 Study to Assess if ABP798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Rituximab Active, not recruiting NCT02792699 Phase 3 ABP 798;Rituximab
46 (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Active, not recruiting NCT02039726 Phase 3 Quizartinib;Salvage Chemotherapy
47 A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) Active, not recruiting NCT02706951 Phase 3 Methotrexate;ABT-494;ABT-494 matching placebo;Methotrexate matching placebo
48 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Active, not recruiting NCT02611830 Phase 3 Vedolizumab IV 300 mg;Placebo IV;Vedolizumab SC 108 mg;Placebo SC
49 Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) Active, not recruiting NCT02239120 Phase 3 optional ASA as comedication;placebo to ASA;placebo to optional ASA as comedication;placebo to dabigatran etexilate;ASA 100 mg;dabigatran etexilate
50 Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis Active, not recruiting NCT01583374 Phase 3 Apremilast tablet 20 mg;Apremilast tablet 30 mg BID;Placebo

Search NIH Clinical Center for Plague

Genetic Tests for Plague

Anatomical Context for Plague

The Foundational Model of Anatomy Ontology organs/tissues related to Plague:

18
Lymph Node, Vasculature Or

MalaCards organs/tissues related to Plague:

38
Lung, Lymph Node, Testes, Spleen, Skin, Thymus, Tonsil

Publications for Plague

Articles related to Plague:

(show top 50) (show all 917)
# Title Authors Year
1
Plague in Madagascar - A Tragic Opportunity for Improving Public Health. ( 29261403 )
2018
2
Of mice and men: Traces of life in the death registries of the 1630 plague in Milano. ( 29305937 )
2018
3
Nine Whole-Genome Assemblies of<i>Yersinia pestis</i>subsp.<i>microtus</i>bv. Altaica Strains Isolated from the Altai Mountain Natural Plague Focus (No. 36) in Russia. ( 29348336 )
2018
4
Molecular epidemiological investigations of plague in Eastern Province of Zambia. ( 29433443 )
2018
5
Human case of bubonic plague resulting from the bite of a wild Gunnison's prairie dog during translocation from a plague-endemic area. ( 29110441 )
2018
6
SCIENTISTS and SCIENCE ADVOCATES: Dr. Younes Karimi (1929-2008), the Prominent Iranian Physician in the Field of Plague and Other Infectious Diseases ( 29380589 )
2018
7
Simultaneous immunodetection of anthrax, plague and tularemia from blood cultures utilizing multiplexed suspension arrays. ( 29386263 )
2018
8
Identifying the social and environmental determinants of plague endemicity in Peru: insights from a case study in Ascope, La Libertad. ( 29409470 )
2018
9
Plague in Madagascar. ( 29316870 )
2018
10
Investigation of Pneumonic Plague, Madagascar. ( 29260670 )
2018
11
The Resistance to Plague Infection among<i>Meriones persicus</i>from Endemic and Non-endemic Regions in Iran: The Role of Gut Microbiota. ( 29318122 )
2018
12
Ecologic Features of Plague Outbreak Areas, Democratic Republic of the Congo, 2004-2014. ( 29350136 )
2018
13
Pneumonic plague epidemic in Northeast China in 1910-1911: Dr. Wu Lien-Teh's epidemic preventive system for plague control. ( 29372498 )
2018
14
Detecting plague-host abundance from space: Using a spectral vegetation index to identify occupancy of great gerbil burrows. ( 29399006 )
2018
15
Madagascar can build stronger health systems to fight plague and prevent the next epidemic. ( 29300731 )
2018
16
Human ectoparasites and the spread of plague in Europe during the Second Pandemic. ( 29339508 )
2018
17
A Field Study of Plague and Tularemia in Rodents, Western Iran. ( 28165869 )
2017
18
Zinc transporters YbtX and ZnuABC are required for the virulence of Yersinia pestis in bubonic and pneumonic plague in mice. ( 28540946 )
2017
19
Plague in a Colony of Gunnison's Prairie Dogs ( Cynomys gunnisoni) Despite Three Years of Infusions of Burrows with 0.05% Deltamethrin to Kill Fleas. ( 29286262 )
2017
20
Temporal and spatial distribution characteristics in the natural plague foci of Chinese Mongolian gerbils based on spatial autocorrelation. ( 28780908 )
2017
21
Comparison of Zoonotic Bacterial Agents in Fleas Collected from Small Mammals or Host-Seeking Fleas from a Ugandan Region Where Plague Is Endemic. ( 29276773 )
2017
22
Model-based analysis of an outbreak of bubonic plague in Cairo in 1801. ( 28637916 )
2017
23
Plenty Is No Plague: Streptomyces Symbiosis with Crops. ( 27916552 )
2017
24
The Live Chicken Treatment for Buboes: Trying a Plague Cure in Medieval and Early Modern Europe. ( 28757495 )
2017
25
Plague: A Millenary Infectious Disease Reemerging in the XXI Century. ( 28904964 )
2017
26
Yersinia pestis halotolerance illuminates plague reservoirs. ( 28054667 )
2017
27
Knowledge and practices related to plague in an endemic area of Uganda. ( 28935246 )
2017
28
Isolation and Suffering Related to Serious and Terminal Illness: Metaphors and Lessons From Albert Camus' Novel, The Plague. ( 28778561 )
2017
29
A Historical View of Motion Sickness-A Plague at Sea and on Land, Also with Military Impact. ( 28421029 )
2017
30
Eight Whole-Genome Assemblies of Yersinia pestis subsp. microtus bv. caucasica Isolated from the Common Vole (Microtus arvalis) Plague Focus in Dagestan, Russia. ( 28839028 )
2017
31
Patterns of Human Plague in Uganda, 2008-2016. ( 28820134 )
2017
32
Pneumonic Plague Transmission, Moramanga, Madagascar, 2015. ( 28221119 )
2017
33
Protein abundances can distinguish between naturally-occurring and laboratory strains of Yersinia pestis, the causative agent of plague. ( 28854255 )
2017
34
Characterization of duck plague virus stability at extreme conditions of temperature, pH and salt concentration. ( 27746073 )
2017
35
Effects of substrate salinity on oviposition, embryonic development and survival in the Australian plague locust, Chortoicetes terminifera (Walker). ( 27742224 )
2017
36
A polymerase chain reaction assay for detection of virulent and attenuated strains of duck plague virus. ( 28860100 )
2017
37
Dynamics of the pneumonic plague epidemic in Madagascar, August to October 2017. ( 29162211 )
2017
38
"Fleaing" the Plague: Adaptations of Yersinia pestis to Its Insect Vector That Lead to Transmission. ( 28886687 )
2017
39
Statistics Commentary Series: Commentary No. 23: A Plague of Decimals: Why Too Much Precision Can be Misleading. ( 28926350 )
2017
40
Vaccines for Conservation: Plague, Prairie Dogs & Black-Footed Ferrets as a Case Study. ( 28879613 )
2017
41
An Epidemic, a Scourge, or a Plague. ( 29323816 )
2017
42
Pneumonic plague outbreak hits cities in Madagascar. ( 28982693 )
2017
43
Paleoproteomics of the Dental Pulp: The plague paradigm. ( 28746380 )
2017
44
Temporal phylogeography of Yersinia pestis in Madagascar: Insights into the long-term maintenance of plague. ( 28873412 )
2017
45
RNA-seq comparative analysis of Peking ducks spleen gene expressionA 24A h post-infected with duck plague virulent or attenuated virus. ( 28903751 )
2017
46
Resistance to the crayfish plague, Aphanomyces astaci (Oomycota) in the endangered freshwater crayfish species, Austropotamobius pallipes. ( 28750039 )
2017
47
Cake culture continues to plague office workers. ( 29269922 )
2017
48
Serological and PCR investigation of Yersinia pestis in potential reservoir hosts from a plague outbreak focus in Zambia. ( 28754138 )
2017
49
The Forgotten Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases. ( 29302150 )
2017
50
Seroprevalence and spatial distribution dynamics of Yersinia pestis antibodies in dogs and cats from plague foci in the State of CearA!, Northeastern Brazil. ( 29340453 )
2017

Variations for Plague

Expression for Plague

Search GEO for disease gene expression data for Plague.

Pathways for Plague

Pathways related to Plague according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.78 CCR5 CD86 DDX58 MYD88
2 11.49 CD86 PECAM1 SELE
3 10.91 PLG SELE
4 10.8 MYD88 SELE
5 10.49 MYD88 PECAM1 SELE

GO Terms for Plague

Biological processes related to Plague according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.26 CCR5 CD86 CDC25C DDX58
2 response to interleukin-1 GO:0070555 9.16 MYD88 SELE
3 leukocyte cell-cell adhesion GO:0007159 8.62 PECAM1 SELE

Molecular functions related to Plague according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 8.62 CCR5 CD86

Sources for Plague

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....